DEF: DaVita 2026 Proxy Statement Overview

DaVita Inc. filed its 2026 Proxy Statement detailing director elections, executive compensation, and 2025 operational performance.

Summary

• The 2026 Annual Meeting is scheduled for June 4, 2026, as a virtual-only event.
• Stockholders will vote on the election of nine directors, ratification of KPMG LLP as auditors, and an advisory vote on executive compensation.
• 2025 financial performance included $2,094 million in adjusted operating income and $10.78 in adjusted diluted earnings per share.
• The company successfully integrated its kidney care program (IKC), reaching profitability ahead of expectations.
• DaVita repurchased 12.7 million shares in 2025, reducing outstanding share count by 15% year-over-year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a stable, well-governed filing that demonstrates resilience in the face of operational headwinds while maintaining consistent long-term strategic execution.

Positives

• IKC program achieved profitability for the first time in its history.
• Teammate engagement reached a five-year high of 85%.
• Successfully expanded international footprint with a key acquisition in Brazil.
• Achieved 100% renewable energy usage for global operations.
• Strong stockholder support with 94% approval of executive compensation at the 2025 meeting.

Negatives

• Treatment volume was negatively impacted by a hurricane-disrupted supply chain, a severe flu season, and a cybersecurity incident.
• Home modalities penetration (14.81%) fell short of the 15.25% target.
• Adjusted free cash flow of $1,024 million was lower than the 2024 figure of $1,162 million.

Risks

• Ongoing cybersecurity and data privacy threats.
• Potential for future regulatory changes impacting healthcare reimbursement.
• Challenges in maintaining high teammate engagement and retention in a competitive labor market.
• Risks associated with the integration of international acquisitions.
• Exposure to interest rate fluctuations.

Future Outlook

The company remains focused on long-term growth targets of 3 to 7 percent adjusted operating income growth and 8 to 14 percent adjusted diluted earnings per share growth, while continuing to advance its IKC program and international expansion.

Management Comments

• We are grateful for the strength, agility, and dedication of our caregivers.
• We emerged from the April cybersecurity incident stronger.
• We strive to be a community first and a company second.

Industry Context

StockSavvy.ai notes that DaVita continues to navigate a challenging healthcare environment by shifting toward value-based care models (IKC) and international diversification, mirroring broader industry trends of moving away from pure fee-for-service dialysis revenue.

Comparison to Industry Standards

• Maintains industry-leading status under the CMS Five-Star Rating System.
• Performance metrics are benchmarked against the S&P Health Care Services Select Industry Index.
• Executive compensation peer group includes major healthcare services firms like HCA Healthcare, Labcorp, and Tenet Healthcare.

Corporate Governance

Related Party Transactions

• The company repurchased 3,386,505 shares from Berkshire Hathaway for approximately $485 million in 2025 under a pre-existing share repurchase agreement.

Stakeholder Impact

• Shareholders benefit from significant share repurchases and consistent long-term growth.
• Teammates benefit from continued investment in career development programs like Clinical Ladders.
• Patients benefit from expanded access to kidney transplants and integrated care models.

Next Steps

• Hold 2026 Annual Meeting of Stockholders on June 4, 2026.
• Release 2025 Community Care report.
• Implement new 2030 ESG goals.

Key Dates

Recommendation

The filing reflects a stable, well-managed company meeting its long-term targets. While the business is resilient, the lack of major growth catalysts or significant surprises suggests a hold position for institutional investors.

Keywords

DaVita, Kidney Care, Dialysis, Proxy Statement, Healthcare, Corporate Governance, Executive Compensation